" class="no-js "lang="en-US"> ZyVersa Therapeutics - Medtech Alert
Sunday, March 26, 2023
ZyVersa Therapeutics | Pharmtech Focus

ZyVersa Therapeutics

About ZyVersa Therapeutics

ZyVersa Therapeutics

ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome ASC inhibitor with potential to treat multiple CNS and other inflammatory diseases. It also includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis (FSGS). VAR 200 has potential to treat other kidney diseases, such as Alport Syndrome and Diabetic Kidney Disease.

Related Story

ZyVersa Therapeutics and University of Miami Awarded a Grant From the Michael J. Fox Foundation to Determine if Inhibition of Microglial Inflammasome Activation With IC100 Blocks Neuroinflammation Driving Parkinson's Disease Pathology

July 28 2022

ZyVersa Therapeutics, Inc. (ZyVersa), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of […]